Taiwan
· Delayed Price · Currency is TWD BioGend Therapeutics Statistics
Total Valuation
BioGend Therapeutics has a market cap or net worth of TWD 4.46 billion. The enterprise value is 3.84 billion.
| Market Cap | 4.46B |
| Enterprise Value | 3.84B |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioGend Therapeutics has 124.26 million shares outstanding. The number of shares has increased by 6.78% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 124.26M |
| Shares Change (YoY) | +6.78% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.11% |
| Owned by Institutions (%) | 2.56% |
| Float | 74.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.21 |
| PB Ratio | 5.09 |
| P/TBV Ratio | 6.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -34.90 |
| EV / Sales | 24.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -33.59 |
Financial Position
The company has a current ratio of 25.33, with a Debt / Equity ratio of 0.01.
| Current Ratio | 25.33 |
| Quick Ratio | 24.69 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.09 |
| Interest Coverage | -596.31 |
Financial Efficiency
Return on equity (ROE) is -13.56% and return on invested capital (ROIC) is -9.17%.
| Return on Equity (ROE) | -13.56% |
| Return on Assets (ROA) | -8.65% |
| Return on Capital (ROIC) | -9.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.16 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.16% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -11.16% |
| 50-Day Moving Average | 37.43 |
| 200-Day Moving Average | 37.39 |
| Relative Strength Index (RSI) | 38.10 |
| Average Volume (20 Days) | 121,641 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioGend Therapeutics had revenue of TWD 156.64 million and -109.93 million in losses. Loss per share was -0.89.
| Revenue | 156.64M |
| Gross Profit | 126.16M |
| Operating Income | -138.94M |
| Pretax Income | -135.04M |
| Net Income | -109.93M |
| EBITDA | -88.48M |
| EBIT | -138.94M |
| Loss Per Share | -0.89 |
Balance Sheet
The company has 633.87 million in cash and 10.37 million in debt, giving a net cash position of 623.50 million or 5.02 per share.
| Cash & Cash Equivalents | 633.87M |
| Total Debt | 10.37M |
| Net Cash | 623.50M |
| Net Cash Per Share | 5.02 |
| Equity (Book Value) | 876.85M |
| Book Value Per Share | 7.06 |
| Working Capital | 696.30M |
Cash Flow
In the last 12 months, operating cash flow was -105.97 million and capital expenditures -8.27 million, giving a free cash flow of -114.23 million.
| Operating Cash Flow | -105.97M |
| Capital Expenditures | -8.27M |
| Free Cash Flow | -114.23M |
| FCF Per Share | -0.92 |
Margins
Gross margin is 80.54%, with operating and profit margins of -88.70% and -70.18%.
| Gross Margin | 80.54% |
| Operating Margin | -88.70% |
| Pretax Margin | -86.21% |
| Profit Margin | -70.18% |
| EBITDA Margin | -56.48% |
| EBIT Margin | -88.70% |
| FCF Margin | -72.92% |
Dividends & Yields
BioGend Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.78% |
| Shareholder Yield | -6.78% |
| Earnings Yield | -2.49% |
| FCF Yield | -2.56% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioGend Therapeutics has an Altman Z-Score of 42.57.
| Altman Z-Score | 42.57 |
| Piotroski F-Score | n/a |